Nuance Pharma is an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset portfolio. Focusing on specialty care, Nuance has established a differentiated combination of commercialized assets and innovative pipeline across respiratory, pain management, emergency care and iron deficiency anemia. With the mission to address critical unmet medical needs in Asia Pacific, Nuance deploys the Dual Wheel model that develops a global leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia as a region.
Mr. Mark Lotter, founder and Chief Executive Officer of Nuance Pharma, has over twenty years’ leadership experience in the China healthcare market. As one of the founding executives of AstraZeneca China, Mr. Lotter pioneered the nationwide nebulization strategy that fostered a billion-dollar respiratory market in the past decade. Being a serial entrepreneur, Mr. Lotter has proven experience and commitment to bringing world-leading innovative therapies to patients in the Asia Pacific region.